Gravity Analytica

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

NBIX 10.09.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-10-30

Name of Upcoming Event:Q3 2024 Conference Call

Full Press Release SEC Filings Our NBIX Tweets

About Gravity Analytica

Recent Filings

Conference Call and Webcast Scheduled forWednesday, October 30

SAN DIEGO,Oct. 9, 2024/PRNewswire/ --Neurocrine Biosciences, Inc.(Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for5:00 a.m. Pacific Time(8:00 a.m. Eastern Time) onOctober 30, 2024.

The schedule for the press release and conference call / webcast is as follows:


• Q3 2024 Press Release:	October 30, 2024at4:00 a.m. PT/7:00 a.m. ET
• Q3 2024 Conference Call:	October 30, 2024at5:00 a.m. PT/8:00 a.m. ET
• Domestic Dial-In Number:	800-225-9448
• International Dial-In Number:	203-518-9708
• Conference ID:	NBIX

The webcast can also be accessed onNeurocrine Biosciences'website under Investors atwww.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

AboutNeurocrine BiosciencesNeurocrine Biosciencesis a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visitneurocrine.com, and follow the company onLinkedIn,X (Formerly Twitter)andFacebook. (*in collaboration with AbbVie)

NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks ofNeurocrine Biosciences, Inc.The Neurocrine logo is a trademark ofNeurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2024-financial-results-302271930.html

SOURCENeurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Tony Jewell (Media), 858-617-7578, media@neurocrine.com; Todd Tushla (Investors), 858-617-7143, ir@neurocrine.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com